SpringerLink
Log in

Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis

  • Published:
Current Medical Science Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Summary

It has been demonstrated that pitavastatin can significantly reduce low-density lipoprotein (LDL) cholesterol (LDL-C), but its impact on lipoprotein subfractions and oxidized low-density lipoprotein (oxLDL) has not been determined. The aim of the present study was to investigate the potential effects of pitavastatin on subfractions of LDL and high-density lipoprotein (HDL) as well as oxLDL in untreated patients with coronary atherosclerosis (AS). Thirty-six subjects were enrolled in this study. Of them, 18 patients with AS were administered pitavastatin 2 mg/day for 8 weeks and 18 healthy subjects without therapy served as controls. The plasma lipid profile, lipoprotein subfractions and circulating oxLDL were determined at baseline and 8 weeks respectively. The results showed that pitavastatin treatment indeed not only decreased LDL-C, total cholesterol (TC), triglycerides (TG) and apolipoprotein B (ApoB) levels, and increased HDL cholesterol (HDL-C), but also reduced the cholesterol concentration of all of the LDL subfractions and the percentage of intermediate and small LDL subfractions. Meanwhile, pitavastatin could decrease plasma oxLDL levels. Furthermore, a more close correlation was found between oxLDL and LDL-C as well as LDL subfractions after pitavastatin treatment. We concluded that a moderate dose of pitavastatin therapy not only decreases LDL-C and oxLDL concentrations but also improves LDL subfractions in patients with AS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol, 2007,50(18):1735–1741

    Article  CAS  Google Scholar 

  2. Reith C, Armitage J.. Management of residual risk after statin therapy. Atherosclerosis, 2016,245:161–170

    Article  CAS  Google Scholar 

  3. Xu RX, Zhang Y, Ye P, et al. Analysis of Lipoprotein Subfractions in Chinese Han Patients with Stable Coronary Artery Disease. Heart Lung Circ, 2015,24(12):1203–1210

    Article  Google Scholar 

  4. Qi Y, Fan J, Liu J, et al. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J Am Coll Cardiol, 2015,65(4):355–363

    Article  CAS  Google Scholar 

  5. Zhu CG, Zhang Y, Xu RX, et al. Circulating non-HDL-C levels were more relevant to atherogenic lipoprotein subfractions compared with LDL-C in patients with stable coronary artery disease. J Clin Lipidol, 2015,9(6):794–800

    Article  Google Scholar 

  6. Voros S, Joshi P, Qian Z, et al. Apoprotein B, small-dense LDL and impaired HDL remodeling is associated with larger plaque burden and more noncalcified plaque as assessed by coronary CT angiography and intravascular ultrasound with radiofrequency backscatter: results from the ATLANTA I study. J Am Heart Assoc, 2013, 2(6):e000344

    Article  Google Scholar 

  7. Joksić J, Sopić M, Spasojević-Kalimanovska V, et al. Higher circulating resistin protein and PBMCs resistin mRNA levels are associated with increased prevalence of small dense LDL particles in coronary artery disease patients. Clin Exp Pharmacol Physiol, 2016,43(1):22–28

    Article  Google Scholar 

  8. Huang YQ, Cai AP, Chen JY, et al. The relationship of plasma mir-29a and oxidized low density lipoprotein with atherosclerosis. Cell Physiol Biochem, 2016,40(6):1521–1528

    Article  CAS  Google Scholar 

  9. Wang A, Yang Y, Su Z, et al. Association of oxidized low-density lipoprotein with prognosis of stroke and stroke subtypes. Stroke, 2017,48(1):91–97

    Article  CAS  Google Scholar 

  10. Zhang L, Jia YH, Zhao XS, et al. Trichosanatine alleviates oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the lox-1/p38 mapk pathway. Am J Transl Res, 2016,8(12):5455–5464

    CAS  Google Scholar 

  11. Barrios V, Escobar C. Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of develo** diabetes. Future Cardiol, 2016,12(4):449–466

    Article  CAS  Google Scholar 

  12. Jeong HS, Hong SJ, Son S, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of develo** diabetes during a 3-year follow-up. Cardiovasc Diabetol, 2019,18(1):162–170

    Article  CAS  Google Scholar 

  13. Vallejo-Vaz AJ, Kondapally Seshasai SR, Kurogi K, Michishita I, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis, 2015,241(2):409–418

    Article  CAS  Google Scholar 

  14. Christogiannis LG, Kostapanos MS, Tellis CC, et al. Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. J Hum Hypertens, 2013,27(1):44–50

    Article  CAS  Google Scholar 

  15. Goliasch G, Oravec S, Blessberger H, et al. Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (</= 40 years of age). Eur J Clin Invest, 2012,42(6):631–636

    Article  CAS  Google Scholar 

  16. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol, 2007,49(5):547–553

    Article  Google Scholar 

  17. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study-Implications for LDL Management. J Clin Lipidol, 2007,1(6):583–592

    Article  Google Scholar 

  18. Toft-Petersen AP, Tilsted HH, Aaroe J, et al.. Small dense LDL particles-a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study. Lipids Health Dis, 2011,10:21–27

    Article  CAS  Google Scholar 

  19. Xu RX, Guo YL, Li XL, et al. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype. Clin Exp Pharmacol Physiol, 2014,41(7):475–481

    Article  CAS  Google Scholar 

  20. Saku K, Zhang B, Noda K, et al. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J, 2011,75(6):1493–1505

    Article  CAS  Google Scholar 

  21. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb, 2007,14(3):128–132

    Article  CAS  Google Scholar 

  22. Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci, 2002,71(20):2403–2412

    Article  CAS  Google Scholar 

  23. Barylski M, Toth PP, Nikolic D, et al. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab, 2014,28(3):453–461

    Article  CAS  Google Scholar 

  24. Kypreos KE, Gkizas S, Rallidis LS, et al. HDL particle functionality as a primary pharmacological target for HDL-based therapies. Biochem Pharmacol, 2013,85(11):1575–1578

    Article  CAS  Google Scholar 

  25. Salonen JT, Salonen R, Seppanen K, et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation, 1991,84(1):129–139

    CAS  Google Scholar 

  26. Kawano M, Nagasaka S, Yagyu H, et al. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb, 2008,15(1):41–46.

    Article  Google Scholar 

  27. Kakuda H, Matoba M, Nakatoh H, et al. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Scand J Clin Lab Invest, 2014,74(4):285–295

    Article  CAS  Google Scholar 

  28. Frostegard J, Zhang Y, Sun J, et al. Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect. J Am Heart Assoc, 2016,5(9):e003976

    Article  Google Scholar 

  29. He L, Xu R, Wang J, et al. Prestroke statins use reduces oxidized low density lipoprotein levels and improves clinical outcomes in patients with atrial fibrillation related acute ischemic stroke. BMC Neurol, 2019,19(1):240–247

    Article  Google Scholar 

  30. Taguchi A, Hayashi S. Study of MDA-LDL by pioglitazone and pitavastatin in patients with type 2 diabetes. Nihon Rinsho, 2011,69(1):100–104

    Google Scholar 

Download references

Author information

Author notes

  1. Both authors contributed equally to this study.

Authors and Affiliations

  1. State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Bei**g, 100037, China

    Rui-xia Xu, Yan Zhang, Yue Zhang, Ya-ru Wu, **ao-lin Li, Yuan-lin Guo, Geng Liu, Qian Dong & Jian-jun Li

Authors
  1. Rui-xia Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yue Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ya-ru Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. **ao-lin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuan-lin Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Geng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qian Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jian-jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jian-jun Li.

Additional information

This work was supported, in part, by Capital Special Foundation of Clinical Application Research (No. Z121107001012015), Capital Health Development Fund (No. 201614035), CAMS Major Collaborative Innovation Project (No. 2016-I2M-1-011) and PUMC Youth Fund (No. 3332018200).

Conflict of Interest Statement

No conflict of interests has been disclosured.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Rx., Zhang, Y., Zhang, Y. et al. Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis. CURR MED SCI 40, 879–884 (2020). https://doi.org/10.1007/s11596-020-2263-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-020-2263-4

Key words

Search

Navigation